Nalaganje...

Ibalizumab: First Global Approval

TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)—a humanised IgG4 monoclonal antibody—as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Drugs
Glavni avtor: Markham, Anthony
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2018
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5988774/
https://ncbi.nlm.nih.gov/pubmed/29675744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-018-0907-5
Oznake: Označite
Brez oznak, prvi označite!